Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2026-02-28
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate VEGFR BP102 with nab-paclitaxe or treatment of
physician's choice (TPC) versus nab-paclitaxe or TPC in patients for basal-like immune
suppressed (BLIS) subtype of triple-negative breast cancer (TNBC) in the first-line teatment
of unresectable locally advanced or metastatic TNBC.